APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...
Overall, tailoring an HIV treatment regimen to individuals’ clinical and social context can help mitigate the persistent barriers to care access. Switching treatment is not just a clinical decision ...
Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback